Advanced glycation end-products (AGEs) and heart failure: Pathophysiology and clinical implications

European Journal of Heart Failure

Volumn 9, Issue 12, 2007, Pages 1146-1155

  Hartog, Jasper W L ^a   Voors, Adriaan A ^a   Bakker, Stephan J L ^a   Smit, Andries J ^a   van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Advanced glycation end products; Atherosclerosis; Cross linking; Heart failure; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ENALAPRIL; ENDOTHELIN 1; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE;

AGING; ATHEROSCLEROSIS; CROSS LINKING; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; GLYCATION; HEART FAILURE; HUMAN; KIDNEY FAILURE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTOLIC HEART FAILURE;

ANIMALS; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; OXIDATIVE STRESS; SYSTOLE;

EID: 36248989151     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.09.009     Document Type: Review

References (55)

1. Miyata T., Sugiyama S., Saito A., and Kurokawa K. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). Kidney Inter Suppl 78 (2001) S25-S31
2. Smit A.J., and Lutgers H.L. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 11 (2004) 2767-2784
3. Monnier V.M., Bautista O., Kenny D., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin collagen ancillary study group. Diabetes control and complications trial. Diabetes 48 (1999) 870-880
4. Meerwaldt R., Lutgers H.L., Links T.P., et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30 (2007) 107-112
5. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21 (2003) 3-12
6. Krum H., and Liew D. New developments in the pharmacological treatment of chronic heart failure. Expert Opin Investig Drugs 12 (2003) 751-757
7. Bakris G.L., Bank A.J., Kass D.A., et al. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 17 (2004) 23S-30S
8. Zieman S.J., and Kass D.A. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 64 (2004) 459-470
9. Monnier V.M., Vishwanath V., Frank K.E., et al. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 314 (1986) 403-408
10. Thornalley P.J. Measurement of protein glycation, glycated peptides, and glycation free adducts. Perit Dial Int 25 (2005) 522-533
11. Hartog J.W., de Vries A.P., Bakker S.J., et al. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Nephrol Dial Transplant 21 (2006) 2263-2269
12. Yoshida S., Yamada K., Hamaguchi K., et al. Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation. Clin Nephrol 49 (1998) 273-280
13. Schleicher E.D., Wagner E., and Nerlich A.G. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99 (1997) 457-468
14. Schalkwijk C.G., Baidoshvili A., Stehouwer C.D., van H. V., and Niessen H.W. Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim Biophys Acta 1636 (2004) 82-89
15. Dyer D.G., Dunn J.A., Thorpe S.R., et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91 (1993) 2463-2469
16. Hartog J.W., de Vries A.P., Lutgers H.L., et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 1043 (2005) 299-307
17. Uribarri J., Peppa M., Cai W., et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 14 (2003) 728-731
18. Cerami C., Founds H., Nicholl I., et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 94 (1997) 13915-13920
19. Brett J., Schmidt A.M., Yan S.D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143 (1993) 1699-1712
20. Striker L.J., and Striker G.E. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant 11 Suppl 5 (1996) 62-65
21. Petrova R., Yamamoto Y., Muraki K., et al. Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34 (2002) 1425-1431
22. Ohgami N., Nagai R., Miyazaki A., et al. Scavenger receptor class B type I-mediated reverse cholesterol transport is inhibited by advanced glycation end products. J Biol Chem 276 (2001) 13348-13355
23. Bucala R., Makita Z., Vega G., et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 91 (1994) 9441-9445
24. Witztum J.L., and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88 (1991) 1785-1792
25. Forbes J.M., Yee L.T., Thallas V., et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53 (2004) 1813-1823
26. Fischer D., Rossa S., Landmesser U., et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 26 (2005) 65-69
27. Borlaug B.A., Melenovsky V., Russell S.D., et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114 (2006) 2138-2147
28. Quehenberger P., Bierhaus A., Fasching P., et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49 (2000) 1561-1570
29. Sanders D.B., Kelley T., and Larson D. The role of nitric oxide synthase/nitric oxide in vascular smooth muscle control. Perfusion 15 (2000) 97-104
30. Yoshida N., Okumura K., and Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 54 (2005) 345-350
31. Kass D.A., Shapiro E.P., Kawaguchi M., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104 (2001) 1464-1470
32. Schafer S., Huber J., Wihler C., et al. Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)-(carboxymethyl) lysine. Eur J Heart Fail 8 (2006) 2-6
33. Berg T.J., Snorgaard O., Faber J., et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22 (1999) 1186-1190
34. Norton G.R., Candy G., and Woodiwiss A.J. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93 (1996) 1905-1912
35. Avendano G.F., Agarwal R.K., Bashey R.I., et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 48 (1999) 1443-1447
36. Thornalley P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419 (2003) 31-40
37. Asif M., Egan J., Vasan S., et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A 97 (2000) 2809-2813
38. Vaitkevicius P.V., Lane M., Spurgeon H., et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A 98 (2001) 1171-1175
39. Little W.C., Zile M.R., Kitzman D.W., et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11 (2005) 191-195
40. Thohan V., Koerner M.M., Pratt C.M., and Torre G.A. Improvements in diastolic function among patients with advanced systolic heart failure utilizing alagebrium (an oral advanced glycation end-product cross-link breaker). Circulation 112 (2005) U620 2647 Suppl 2
41. Chang K.C., Hsu K.L., Chou T.F., Lo H.M., and Tseng Y.Z. Aminoguanidine prevents age-related deterioration in left ventricular-arterial coupling in Fisher 344 rats. Br J Pharmacol 142 (2004) 1099-1104
42. Liu J., Masurekar M.R., Vatner D.E., et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 285 (2003) H2587-H2591
43. Cheng G., Wang L.L., Qu W.S., et al. C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats. Acta Pharmacol Sin 26 (2005) 1460-1466
44. Heidland A., Sebekova K., Frangiosa A., et al. Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation. Heart 90 (2004) 1269-1274
45. Koyama Y., Takeishi Y., Arimoto T., et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail 13 (2007) 199-206
46. Parthenakis F.I., Kanoupakis E.M., Kochiadakis G.E., et al. Left ventricular diastolic filling pattern predicts cardiopulmonary determinants of functional capacity in patients with congestive heart failure. Am Heart J 140 (2000) 338-344
47. Peyroux J., and Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol (Paris) 54 (2006) 405-419
48. Monnier V.M. Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 419 (2003) 1-15
49. Miyata T., and van Ypersele dS. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 419 (2003) 50-54
50. Foley R.N., Murray A.M., Li S., et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16 (2005) 489-495
51. Meerwaldt R., Hartog J.W., Graaff R., et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16 (2005) 3687-3693
52. Goldin A., Beckman J.A., Schmidt A.M., and Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
53. Hartog J.W., Smit A.J., van Son W.J., et al. Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. Am J Kidney Dis 43 (2004) 966-975
54. Tanaka N., Yonekura H., Yamagishi S., et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275 (2000) 25781-25790
55. Hartog JWL, Voors AA, Schalkwijk CG, et al. Clinical and prognostic value of advanced glycation end-products (AGEs) in chronic heart failure. Eur Heart J in press.